Baluwala I, Favaloro EJ, Pasalic L (2017) Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol 10:595–605. https://doi.org/10.1080/17474086.2017.1345306

Article  PubMed  CAS  Google Scholar 

Dean CL (2023) An overview of Heparin Monitoring with the Anti-xa Assay. Methods Mol Biol 2663:343–353. https://doi.org/10.1007/978-1-0716-3175-1_22

Article  PubMed  CAS  Google Scholar 

Onishi A, St Ange K, Dordick JS, Linhardt RJ (2016) Heparin and anticoagulation. Front Biosci (Landmark Ed) 21: 1372-92. https://doi.org/10.2741/4462

Ouyang Y, Yu Y, Zhang F, Chen J, Han X, Xia K, Yao Y, Zhang Z, Linhardt RJ (2019) Non-anticoagulant low Molecular Weight Heparins for Pharmaceutical Applications. J Med Chem 62:1067–1073. https://doi.org/10.1021/acs.jmedchem.8b01551

Article  PubMed  CAS  Google Scholar 

Beurskens DMH, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperge CP, Nicolaes GAF (2020) The Anticoagulant and Nonanticoagulant Properties of Heparin. Thromb Haemost 120: 1371–1383. https://doi.org/10.1055/s-0040-1715460

Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J, Organization to Assess Strategies for Ischemic Syndromes, Investigators(2003) Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 107: 2884-8. https://doi.org/10.1161/01.CIR.0000077530.53367.E9

Francis JL, Groce JB 3rd, Heparin Consensus Group (2004) Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy 24:108S–119S. http://doi.Group

Article  PubMed  CAS  Google Scholar 

Gouin-Thibault I, Mansour A, Hardy M, Gueret P, de Maistre E, Siguret V, Cuker A, Mullier F, Lecompte T (2024) Management of therapeutic-intensity Unfractionated Heparin: a narrative review on critical points. TH Open 8:e297–e307. https://doi.org/10.1055/a-2359-0987

Article  PubMed  PubMed Central  Google Scholar 

Samimi MN, Hale A, Schults J, Fischer A, Roberts JA, Dhanani J (2024) Clinical guidance for unfractionated heparin dosing and monitoring in critically ill patients. Expert Opin Pharmacother 25:985–997. https://doi.org/10.1080/14656566.2024.2364057

Article  PubMed  CAS  Google Scholar 

Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e24S-e43S. https://doi.org/10.1378/chest.11-2291

Taneja R, Berry L, Pappu U, Stitt L, Sayal P, Allen P, Hoogendoorn H, Chan A (2014) Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard. J Cardiothorac Vasc Anesth 28:1227–1232. https://doi.org/10.1053/j.jvca.2014.04.024

Article  PubMed  CAS  Google Scholar 

Smahi M, De Pooter N, Hollestelle MJ, Toulon P (2020) Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents. J Thromb Haemost 18: 2613–2621. https://doi.org/10.1111/jth.14969

Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, Kickler T (2013) Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 139: 450-6. https://doi.org/10.1309/AJCPS6OW6DYNOGNH

Hollestelle MJ, Van Der Meer FJM, Meijer P (2020) Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data. Clin Chem Lab Med 58:1921–1930. https://doi.org/10.1515/cclm-2020-0130

Article  PubMed  CAS  Google Scholar 

Hardy M, Cabo J, Deliege A, Douxfils J, Gouin-Thibault I, Lecompte T, Mullier F (2023) Reassessment of dextran sulfate in anti-xa assay for unfractionated heparin laboratory monitoring. Res Pract Thromb Haemost 7:102257. https://doi.org/10.1016/j.rpth.2023.102257

Article  PubMed  PubMed Central  Google Scholar 

Mouton C, Calderon J, Janvier G, Vergnes MC (2003) Dextran sulfate included in factor xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine. Thromb Res 111:273–279. https://doi.org/10.1016/j.thromres.2003.09.014

Article  PubMed  CAS  Google Scholar 

Jia Z, Tian G, Ren Y, Sun Z, Lu W, Hou X (2015) Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Transl Med 13: 45. https://doi.org/10.1186/s12967-015-0404-5

Lasne D, Toussaint-Hacquard M, Delassasseigne C, Bauters A, Flaujac C, Savard P, Mouton C, De Maistre E, Stepanian A, Eschwege V, Delrue M, Georges JL, Gros A, Mansour A, Leroy G, Jouffroy R, Mattei M, Beurton A, Pontis A, Neuwirth M, Nedelec-Gac F, Lecompte T, Curis E, Siguret V, Gouin-Thibault I (2024) Factors influencing anti-xa assays: a Multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin. Thromb Haemost 123:1105–1115. https://doi.org/10.1055/s-0043-1770096

Article  Google Scholar 

Hammami E, Stiel L, Palpacuer C, Harzallah I (2023) Heparin monitoring during extracorporeal membrane oxygenation: the effect of dextran sulfate on anti-xa assay. Res Pract Thromb Haemost 7:102196. https://doi.org/10.1016/j.rpth.2023.102196

Article  PubMed  PubMed Central  Google Scholar 

Boer C, Meesters MI, Veerhoek D, Vonk ABA (2018) Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth 120: 914–927. https://doi.org/10.1016/j.bja.2018.01.023